References
2. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med 2017;376:254–266.
3. Ward ZJ, Bleich SN, Long MW, et al. Association of body mass index with health care expenditures in the United States by age and sex. PLoS ONE 2021;16:e0247307.
5. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010;71:1259–1272.
6. Deshmukh R, Franco K. Managing weight gain as a side effect of antidepressant therapy. Cleve Clin J Med 2003;70:614, 616, 618, passim.
7. Dent R, Blackmore A, Peterson J, et al. Changes in body weight and psychotropic drugs: a systematic synthesis of the literature. PLoS ONE 2012;7:e36889.
8. Harris B, Young J, Hughes B. Comparative effects of seven antidepressant regimes on appetite, weight and carbohydrate preference. Br J Psychiatry 1986;148:590–592.
9. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000;61(Suppl 11):37-41.
10. Alam MY, Jacobsen PL, Chen Y, et al. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol 2014;29:36–44.
11. Bathla M, Anjum S. A 12-week prospective randomized controlled comparative trial of vilazodone and sertraline in Indian patients with depression. Indian J Pharmacol 2020;52: 10–15.
12. Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 1994;14:170–179.
13. Gadde KM, Xiong GL. Bupropion for weight reduction. Expert Rev Neurother 2007;7:17–24.
14. Anekwe CV, Ahn YJ, Bajaj SS, et al. Pharmacotherapy causing weight gain and metabolic alteration in those with obesity and obesity-related conditions: a review. Ann NY Acad Sci 2024;1533:145–155.
15. Domecq JP, Prutsky G, Leppin A, et al. Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab 2015;100: 363–370.
16. Ratliff JC, Barber JA, Palmese LB, et al. Association of prescription H1 antihistamine use with obesity: results from the National Health and Nutrition Examination Survey. Obesity (Silver Spring) 2010;18:2398–2400.
17. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes—causes, effects and coping strategies. Diabetes Obes Metab 2007;9:799–812.
18. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–2443.
19. Yerevanian A, Soukas AA. Metformin: mechanisms in human obesity and weight loss. Curr Obes Rep 2019;8:156–164.
20. Schnell O, Weng J, Sheu WHH, et al. Acarbose reduces body weight irrespective of glycemic control in patients with diabetes: results of a worldwide, non-interventional, observational study data pool. J Diabetes Complications 2016;30:628–637.
21. Sugimoto S, Nakajima H, Kosaka K, et al. Review: miglitol has potential as a therapeutic drug against obesity. Nutr Metab 2015;12:51.
22. Ribola FA, Cançado FB, Schoueri JH, et al. Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci 2017;21:199-211.
23. Powell J, Taylor J. Use of dulaglutide, semaglutide, and tirzepatide in diabetes and weight management. Clin Ther 2024;46:289-292.
24. Wung PK, Anderson T, Fontaine KR, et al.Effects of glucocorticoids on weight change during the treatment of Wegener’s granulomatosis.Arthritis Rheum 2008;59:746–753.
25. Verhaegen AA, Van Gaal LF. Drugs That Affect Body Weight, Body Fat Distribution, and Metabolism. South Dartmouth, MA: MDText.com; 2019.
26. Wharton S, Raiber L, S4erodio KJ, et al. Medications that cause weight gain and alternatives in Canada: a narrative review. Diabetes Metab Syndr Obes Targets Ther 2018;11:427–438.
27. Amatayakul K, Sivasomboon B, Thanangkul O. A study of the mechanism of weight gain in medroxyprogesterone acetate users. Contraception 1980;22:605–622.
28. Chandiwana NC, Siedner MJ, Marconi VC, et al. Weight gain after HIV therapy initiation: pathophysiology and implications. J Clin Endocrinol Metab 2024;109:e478– e487.